(Q44606744)

English

Tacrolimus, a Potential Neuroprotective Agent, Ameliorates Ischemic Brain Damage and Neurologic Deficits after Focal Cerebral Ischemia in Nonhuman Primates

scientific article published on October 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Tacrolimus, a potential neuroprotective agent, ameliorates ischemic brain damage and neurologic deficits after focal cerebral ischemia in nonhuman primates (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Tacrolimus, a Potential Neuroprotective Agent, Ameliorates Ischemic Brain Damage and Neurologic Deficits after Focal Cerebral Ischemia in Nonhuman Primates (English)

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

0 references

cerebral infarction

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

author name string

Yasuhisa Furuichi

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Masashi Maeda

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Akira Moriguchi

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Taiji Sawamoto

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Akio Kawamura

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Nobuya Matsuoka

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Seitaro Mutoh

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Takehiko Yanagihara

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14526229

17 March 2024

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

full work available at URL

https://journals.sagepub.com/doi/pdf/10.1097/01.WCB.0000088761.02615.EB

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14526229

17 March 2024

http://journals.sagepub.com/doi/pdf/10.1097/01.WCB.0000088761.02615.EB

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

http://journals.sagepub.com/doi/full-xml/10.1097/01.WCB.0000088761.02615.EB

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Journal of Cerebral Blood Flow & Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1183-1194

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

https://scigraph.springernature.com/pub.10.1097/01.wcb.0000088761.02615.eb

0 references

Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism.

3

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

4

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

The protective action of chlormethiazole against ischaemia‐induced neurodegeneration in gerbils when infused at doses having little sedative or anticonvulsant activity

5

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI.

6

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo

7

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy

8

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

The arterial and venous blood supplies to the forebrain (including the internal capsule) of primates.

9

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls?

10

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

E-selectin appears in nonischemic tissue during experimental focal cerebral ischemia

11

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

FK506 prevents stroke-induced generation of ceramide and apoptosis signaling

12

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis.

14

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model

15

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Experimental thromboembolic stroke in cynomolgus monkey.

16

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

17

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results

18

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Clomethiazole protects against hemineglect in a primate model of stroke

20

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Functional benefit from clomethiazole treatment after focal cerebral ischemia in a nonhuman primate species.

21

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Dose-response analysis of the effect of 21-aminosteroid tirilazad mesylate (U-74006F) upon neurological outcome and ischemic brain damage in permanent focal cerebral ischemia.

23

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). The RANTTAS Investigators

24

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization

25

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Brain volume estimation from serial section measurements: a comparison of methodologies

26

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia

27

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Recommendations for standards regarding preclinical neuroprotective and restorative drug development

29

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Recommendations for clinical trial evaluation of acute stroke therapies.

30

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

The effect of chlormethiazole on neuronal damage in a model of transient focal ischaemia

31

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion.

32

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Tirilazad treatment does not decrease early brain injury after transient focal ischemia in cats.

34

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia

35

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Implications of CAD and DNase II in ischemic neuronal necrosis specific for the primate hippocampus

36

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia.

37

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD

38

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Experimental regional cerebral ischemia in the middle cerebral artery territory in primates. Part 2: Effects on brain water and electrolytes in the early phase of MCA stroke

39

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils

40

1 reference

10.1097/01.WCB.0000088761.02615.EB

https://api.crossref.org/works/10.1097/01.WCB.0000088761.02615.EB

17 March 2024

Identifiers

10.1097/01.WCB.0000088761.02615.EB

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44606744&oldid=2106079435"